BMY - Replimune rebounds despite analyst downgrades on FDA rejection
2025-07-23 11:34:20 ET
More on Replimune Group
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript
- Replimune Group: Analysts Are More Optimistic Than The Market
- Iovance climbs after FDA rejection for Replimune’s skin cancer drug
- Replimune plunges as FDA rejects its lead drug for skin cancer